CSTONE PHARMA-B

CStone Pharmaceuticals rose 3.1% to HK$4.32 today, primarily supported by CS2009's trispecific cancer antibody securing dual rapid oral slots at ESMO 2026 and management's recent shareholding increase. Intraday action showed stark divergence: the morning session surged from HK$4.20 open to HK$4.42 high at 10:06 BJ (up 4%), but the afternoon session faced profit-taking after the strong rally, closing at HK$4.32 by 16:00 BJ. Recent product momentum extends across multiple programs—pralsetinib launched nationwide distribution in China, sugemalimab secured exclusive commercialization deal with Arrotex for Australia and New Zealand, and new EGFR/HER3 bispecific ADC entered global Phase I trials. However, fundamentals reveal a troubling picture: while Q4 operating revenue surged 50.35% year-over-year to HK$122.4M, net loss deteriorated 63.11% to -HK$92.8M with a crushing -75.78% net margin, reflecting accelerating cash burn. Stock price-wise, shares have declined 19.1% year-to-date and plunged 67.15% from 52-week highs of HK$13.15, currently trading below both 20-day (HK$4.83) and 60-day (HK$5.71) moving averages, signaling ongoing technical weakness.

CStone Pharmaceuticals fell 3.68% to HK$4.19 from the previous close of HK$4.35, reflecting profit-taking pressure despite recent positive developments. The trispecific antibody CS2009 earned dual rapid oral presentation slots at the European Society for Medical Oncology ESMO 2026 conference, sugemalimab secured an exclusive commercialization agreement with Arrotex for Australia and New Zealand, and management continued share increases. However, Q4 2025 earnings reveal a widening gap: operating revenue grew 50.35% year-over-year to HK$122.4 million, yet net loss expanded to HK$92.8 million, deteriorating 63.11% worse than the prior year with net margin sinking to negative 75.78%. This highlights the disconnect between pipeline progress and actual monetization capability. The stock has slid 68.14% from the 52-week high of HK$13.15 to HK$4.19, declining 21.54% year-to-date, approaching the 52-week low of HK$4.01 yet still trading at a valuation premium.

CStone Pharmaceuticals declined 3.1% to close at HK$4.41 today, pressured by persistent net losses and weakness in biotech sentiment; volume totaled 3.34 million shares with HK$14.7 million in turnover, with morning trading relatively stable and afternoon weakness evident. The company continues advancing its oncology pipeline with its trispecific antibody CS2009 gaining dual oral presentation slots at ESMO 2026, sugeralimab expanding into Australia and New Zealand markets, and ASCO 2026 data released, while management signaled confidence through ongoing share buybacks. Financially, Q4 revenue surged 50.35% year-over-year to HK$122 million, Q3 revenue grew 41.86% year-over-year to HK$120 million, reflecting strong product uptake, though net profit margin remains deeply negative at -75.78% as the company navigates a high-investment phase in commercialization and R&D. Valuation has compressed notably—share price is down 17.42% year-to-date, down 66.46% from its 52-week high of HK$13.15, and currently trades below both its 20-day moving average of HK$4.95 and 60-day moving average of HK$5.97.

CStone Pharmaceuticals fell about 1.5% to HK$4.55 today, as market concerns over widening losses offset recent positive catalysts, with the stock trading 65.4% below its 52-week high of HK$13.15 and down 14.79% year-to-date. CS2009 trispecific antibody secured rapid oral presentation slots at ESMO 2026 backed by ASCO 2026 clinical data, pralsetinib's nationwide rollout in China drove Q4 revenue to HK$122.4M (up 50.3% YoY), and management's recent shareholding boost signals confidence. However, net losses continued to widen with Q4 loss of HK$92.8M (down 63.1% YoY) and a persistent -75.8% net margin, reflecting high R&D spending typical of early-stage oncology companies. The stock trades below both 20-day (HK$4.97) and 60-day (HK$6.05) moving averages while remaining unprofitable with EPS of -HK$0.0634.

CStone Pharmaceuticals retreated about 5.3% to 4.62 HKD today, likely driven by profit-taking following recent positive catalysts including management shareholding boosts, clinical data presentations of CS2009 trispecific antibody at major conferences like ASCO and ESMO, and ongoing commercialization progress for sugemalimab overseas. Despite robust top-line momentum—Q4 revenue surged 50.35% year-over-year to HKD 122.4 million—the company remains deeply unprofitable with net losses widening to HKD -92.75 million (down 63.11% year-over-year) and net margin of -75.78%. Technically, the stock has plunged roughly 65% from its 52-week high of HKD 13.15 and now trades just 15.21% above the 52-week low of HKD 4.01, with year-to-date decline of 13.48%, reflecting market uncertainty about profitability inflection timing. While management's recent stake increase signals conviction, persistent and widening losses remain a significant headwind.